

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**COMMON SPLENDOR INTERNATIONAL
HEALTH INDUSTRY GROUP LIMITED**

(Incorporated in Bermuda with limited liability)

(Stock Code: 286)

**SUPPLEMENTAL ANNOUNCEMENT
IN RELATION TO
CAPITAL CONTRIBUTION IN AND ACQUISITION OF
100% EQUITY INTEREST IN
FENGSHUO BIO MEDICAL TECH AND
51% EQUITY INTEREST IN
GUANGDONG KELV BIO MEDICAL TECH COMPANY LIMITED
AND
CAPITAL CONTRIBUTION TO OBTAIN 28%
EQUITY INTEREST IN FENGYUAN HUAKE BIO TECH**

Reference is made to the announcements dated 23 November 2015 and 30 November 2018 (the “**Announcements**”), 28 March 2018, 6 September 2018, 6 November 2018 and 19 December 2018 of Common Splendor International Health Industry Group Limited (the “**Company**”). Unless the context otherwise states, capitalised terms used in this announcement have the same meanings as those defined in the Announcements.

2018 GUARANTEE NET PROFIT

Pursuant to the Supplemental Agreement, Target Company No. 1 has undertaken that the 2018 Guarantee Net Profit will not be less than the Guarantee Profit RMB20 million.

As at the date of this announcement, Target Company No. 1 is in the progress of preparing its audited financial statements for the year ended 31 December 2018 (“**FY2018**”), and the amount of actual net profit of Target Company No. 1 for FY2018 (“**Actual 2018 Net Profit**”) was not available when the Company’s 2018 Annual Report was published.

The Company was informed by Target Company No.1 that its audited financial statements for FY2018, containing the amount of Actual 2018 Net Profit, is expected to be available in or around November 2019.

Further announcement(s) will be made by the Company as and when appropriate to keep the shareholders and prospective investors of the Company informed of the latest information in respect of the 2018 Guarantee Net Profit and the amount of Actual 2018 Net Profit.

By Order of the Board
Common Splendor International
Health Industry Group Limited
Cheung Wai Kuen
Chairman

Hong Kong, 1 November 2019

As at the date of this announcement, the Board comprises Mr. Cheung Wai Kuen and Mr. Ye Jiong Xian as executive Directors; Mr. Lin Jiang, Mr. Hou Kai Wen and Mr. Wong Kin Man as non-executive Directors; and Mr. Mai Yang Guang, Mr. Lam Chi Wing and Mr. Wong Yiu Kit, Ernest as independent non-executive Directors.